Evidence map›Paper›PMID 34992581›Full record

ArticleFrontiers in endocrinology2021

A Silent Corticotroph Pituitary Carcinoma: Lessons From an Exceptional Case Report.

Pablo Remón-Ruiz, Eva Venegas-Moreno, Elena Dios-Fuentes, Juan Manuel Canelo Moreno, Ignacio Fernandez Peña, Miriam Alonso Garcia, Miguel Angel Japón-Rodriguez, Florinda Roldán, Elena Fajardo, Ariel Kaen and 3 more

Open access · goldAbstract readCase Reports
In one paragraph

Article in Frontiers in endocrinology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.5field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 4 institutions in 1 country.

Pablo Remón-RuizUnidad de Gestión Clínica de Endocrinología y Nutrición, Instituto de Biomedicina de Sevilla (IBiS), Virgen del Rocio University Hospital/Centro Superior de Investigaciones Científicas (CSIC)/University of Seville, Seville, Spain.
Eva Venegas-MorenoUnidad de Gestión Clínica de Endocrinología y Nutrición, Instituto de Biomedicina de Sevilla (IBiS), Virgen del Rocio University Hospital/Centro Superior de Investigaciones Científicas (CSIC)/University of Seville, Seville, Spain.
Elena Dios-FuentesUnidad de Gestión Clínica de Endocrinología y Nutrición, Instituto de Biomedicina de Sevilla (IBiS), Virgen del Rocio University Hospital/Centro Superior de Investigaciones Científicas (CSIC)/University of Seville, Seville, Spain.
Juan Manuel Canelo MorenoUnidad de Gestión Clínica de Endocrinología y Nutrición, Instituto de Biomedicina de Sevilla (IBiS), Virgen del Rocio University Hospital/Centro Superior de Investigaciones Científicas (CSIC)/University of Seville, Seville, Spain.
Ignacio Fernandez PeñaUnidad de Gestión Clínica de Endocrinología y Nutrición, Virgen de Valme University Hospital, Seville, Spain.
Miriam Alonso GarciaUnidad de Gestión Clínica de Oncología médica, Oncología Radioterápica y Radiofísica Hospitalaria, Virgen del Rocio University Hospital, Seville, Spain.
Miguel Angel Japón-RodriguezUnidad de Gestión Clínica de Anatomía Patológica, Virgen del Rocio University Hospital, Seville, Spain.
Florinda RoldánUnidad de Gestión de Radiodiagnóstico, Virgen del Rocio University Hospital, Seville, Spain.
Elena FajardoUnidad de Gestión de Radiodiagnóstico, Virgen del Rocio University Hospital, Seville, Spain.
Ariel KaenUnidad de Gestión Clínica de Neurocirugía, Virgen del Rocío University Hospital, Seville, Spain.
Eugenio Cardenas Ruiz-ValdepeñasUnidad de Gestión Clínica de Neurocirugía, Virgen del Rocío University Hospital, Seville, Spain.
David CanoUnidad de Gestión Clínica de Endocrinología y Nutrición, Instituto de Biomedicina de Sevilla (IBiS), Virgen del Rocio University Hospital/Centro Superior de Investigaciones Científicas (CSIC)/University of Seville, Seville, Spain.
Alfonso Soto-MorenoUnidad de Gestión Clínica de Endocrinología y Nutrición, Instituto de Biomedicina de Sevilla (IBiS), Virgen del Rocio University Hospital/Centro Superior de Investigaciones Científicas (CSIC)/University of Seville, Seville, Spain.
Hospital Universitario Virgen del Rocío · ESUniversidad de Sevilla · ESHospital Universitario de Valme · ESInstituto de Biomedicina de Sevilla · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Nowadays, neither imaging nor pathology evaluation can accurately predict the aggressiveness or treatment resistance of pituitary tumors at diagnosis. However, histological examination can provide useful information that might alert clinicians about the nature of pituitary tumors. Here, we describe our experience with a silent corticothoph tumor with unusual pathology, aggressive local invasion and metastatic dissemination during follow-up. We present a 61-year-old man with third cranial nerve palsy at presentation due to invasive pituitary tumor. Subtotal surgical approach was performed with a diagnosis of silent corticotroph tumor but with unusual histological features (nuclear atypia, frequent multinucleation and mitotic figures, and Ki-67 labeling index up to 70%). After a rapid regrowth, a second surgical intervention achieved successful debulking. Temozolomide treatment followed by stereotactic fractionated radiotherapy associated with temozolomide successfully managed the primary tumor. However, sacral metastasis showed up 6 months after radiotherapy treatment. Due to aggressive distant behavior, a carboplatine-etoposide scheme was decided but the patient died of urinary sepsis 31 months after the first symptoms. Our case report shows how the presentation of a pituitary tumor with aggressive features should raise a suspicion of malignancy and the need of follow up by multidisciplinary team with experience in its management. Metastases may occur even if the primary tumor is well controlled.

Indexed as

AdenomaCorticotrophsFatal OutcomeHumansMaleMiddle AgedPituitary Neoplasmspituitary carcinomapituitary tumorradiotherapysilent corticothoph tumortemozolomide

Identifiers

PMID34992581
PMCPMC8725817
OpenAlexW4200274498

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.